You raise an interesting point - even at max capacity Sinochem cannot supply enough API to cover all existing V scrips - can an insurer really refuse to cover an available brand name when no other drug exists to treat that indication, leaving patients at risk with no options? This is not a "matter of weeks" issue - there are vast areas in the US where GV will not be available until more generics come to market - some patients are going to go months w/o V or GV, but I'm not sure there's anything those patients can do about it. For instance, I use an inhaler when I get an asthma attack, my BP skyrockets and I get tachycardia - clearly an acute CVE risk situation, but for years no Medicare Part D plans covered inhalers, so I was SOL, had to buy it from Canada and pay out of pocket. So maybe BCBS really can say "sucks to be you if GV isn't available"?
Market Data 
Markets 
AI
